Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

Mereo BioPharma Q3 2026: Cash Falls to $26.1M

Mereo BioPharma Group plc filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting a net cash position of $26.1 million and a widening accumulated deficit.

Anjali Anand | 09 November 2026

Quanterix Posts Q3 2026 Revenue of $34.97M

Quanterix Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting total revenues of $34,974 thousand for the third quarter and $104,295 thousand for the nine months ended September …

Shwetambri Chauhan | 09 November 2026

SS&C Technologies Prices $1.2B Convertible Notes Due 2031

SS&C Technologies Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing the completion of a $1,200,000,000 aggregate principal amount offering of 2.75% Convertible Senior Notes due 2031, with the transaction closing on November 6, 2026.

Anjali Anand | 09 November 2026

Sonoco Names Haynes CEO as Coker Retires Dec. 31

Sonoco Products Company filed a Form 8-K on November 9, 2026, disclosing the planned retirement of President and CEO R. Howard Coker effective December 31, 2026, the appointment of Ernest D. Haynes III as his successor, and a retention award for Chief Financial Officer …

Aditi Sarkar | 09 November 2026

Innovative Industrial Properties Adds Series B Preferred to ATM Program

Innovative Industrial Properties, Inc. filed a Form 8-K on November 9, 2026, disclosing amendments to its existing equity distribution agreements that add the company's 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program.

Manish Choudhary | 09 November 2026

Cellebrite Q3 2026 Call Dial-In Revised Before Nov. 12 Event

Cellebrite DI Ltd. filed an announcement on November 9, 2026, notifying analysts and investors that the call-in number for its third-quarter 2026 financial results conference call had been updated, while all other details for the November 12, 2026 event remained unchanged from the October …

Manish Choudhary | 09 November 2026

K2 Principal Fund Discloses 7.74% Stake in Newbury Street II

A Schedule 13G was filed on November 9, 2026, by The K2 Principal Fund, L.P. and three affiliated entities disclosing beneficial ownership of 241,100 Class A Ordinary Shares of Newbury Street II Acquisition Corp as of November 4, 2026.

Aakashdeep | 09 November 2026

Vir Biotechnology ECLIPSE 1 Phase 3 Trial Meets Primary Endpoint

Vir Biotechnology, Inc. filed a Form 8-K on November 9, 2026, disclosing topline results from its pivotal Phase 3 ECLIPSE 1 clinical trial and expanded Week 96 data from the Phase 2 SOLSTICE study, both evaluating elebsiran and tobevibart in adults with chronic hepatitis …

Aditi Sarkar | 09 November 2026

Empery Digital Repurchases 155,040 Shares at $2.36 Average

Empery Digital Inc. filed a Form 8-K on November 9, 2026, disclosing share repurchase activity for the week ended November 6, 2026, and providing an update on lease negotiations for its Midwest data center investment through EMHU LLC.

Anjali Anand | 09 November 2026

Ionis Pharmaceuticals Q3 2026: Net Loss Narrows to $110M

Ionis Pharmaceuticals, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting financial results for the three and nine months ended on that date.

Anjali Anand | 09 November 2026
Support

Hi! How can we help you today?

Loading…